Declaration of interests PM has received honoraria as a consultant for Abbott, Biomea Fusion, Dexcom, Insulet, Minimed (Medtronic), and Novo Nordisk, and is a member of the speakers’ bureau for Abbott, Dexcom, Insulet, Minimed (Medtronic), and Novo Nordisk. VRA reports institutional contracts with Amgen, Applied Therapeutics, AstraZeneca, Biomea Fusion, Corcept Therapeutics, Eli Lilly, Fractyl Health, Kailera Therapeutics, Novo Nordisk, Pfizer, Recordati, Rhythm Pharmaceuticals, and Servier, and has received consultancy fees from the Baim Institute for Clinical Research, Mediflix, Roche, and Sanofi. MB has received honoraria as a consultant and speaker from Abbott, Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Daiichi–Sankyo, Lilly, MSD, Novo Nordisk, Novartis, Pfizer, and Sanofi, and reports chairing a clinical trial data safety monitoring board for Boehringer Ingelheim. MA, A-LFC, MK, and LNV are employees and shareholders of Novo Nordisk. JR reports clinical research grants from Amgen, Applied Therapeutics, AstraZeneca, Biomea Fusion, Boehringer Ingelheim, Corcept Therapeutics, Corxel, Eli Lilly, Hanmi Pharmaceutical, Merck, Novo Nordisk, Pfizer, Regeneron, Roche, Regor Therapeutics, Sanofi, Structure Therapeutics, and Terns Pharma; serves or has served on scientific advisory boards for, and has received honoraria or consulting fees from, Amgen, Applied Therapeutics, Arrowhead Pharmaceuticals, Biomea Fusion, Boehringer Ingelheim, Corcept, Eccogene, Eli Lilly, Hanmi Pharmaceutical, i2O Therapeutics, Novo Nordisk, Regeneron, Roche, Sanofi, Structure Therapeutics, and Terns Pharma; and has received honoraria for lectures from Eli Lilly, Novo Nordisk, and Sanofi.
PubMed
